Neonatal Abstinence Syndrome Due to Maternal Kratom Use.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30404789.
- Also identified by DOI 10.1542/peds.2018-1839.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neonatal abstinence syndrome (NAS) is increasing in incidence and most commonly associated with maternal opioid use during pregnancy. Nonopioid alternatives to treat opioid dependence are highly sought after in the country's current opioid epidemic. Whether Kratom, a legal, widely available herbal supplement, should be classified as an opioid is contentious. Although the US Food and Drug Administration has recently addressed this controversy, Kratom continues to be marketed as a nonopioid remedy for opioid withdrawal. Its use is increasing in the United States. We describe an infant with NAS born to a mother with daily Kratom tea ingestion to self-treat opioid dependence. Pediatricians and parents should be aware of the risk of NAS due to Kratom use during pregnancy.
Medical subject headings
- Marijuana Abuse
- Mitragyna
- Neonatal Abstinence Syndrome
- Prenatal Exposure Delayed Effects